BridgeBio Pharma, Inc. (BBIO)
Health Care ยท Pharmaceutical Preparations
BridgeBio Pharma, Inc. (BBIO) is listed on Nasdaq, where its shares have traded since June 27, 2019. SentiSense covers BridgeBio Pharma, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Neil Kumar is its chief executive officer. The company reports 839 employees, and its corporate website is www.bridgebio.com.
About BridgeBio Pharma, Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 461 institutions reported holding BBIO, with 193.3 million shares worth $14.4 billion in aggregate. The largest reported holders were Vanguard, Janus Henderson (Jupiter Topco) and Kohlberg Kravis Roberts & Co.. Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
More on BBIO
- BBIO sentiment: whether news and social coverage of BridgeBio Pharma, Inc. leans bullish or bearish, and the stories driving it.
- BBIO ownership: all 461 reporting institutions, plus insider and congressional trades.
- BBIO financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for BridgeBio Pharma, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does BridgeBio Pharma, Inc. do?
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases.
What sector is BBIO in?
SentiSense classifies BridgeBio Pharma, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does BBIO stock trade?
BridgeBio Pharma, Inc. (BBIO) is listed on Nasdaq, where its shares have traded since June 27, 2019.
Who is the CEO of BridgeBio Pharma, Inc.?
Neil Kumar is the chief executive officer of BridgeBio Pharma, Inc..